Recent Updates
Recently added Catalysts

ZILRETTA

Phase 3

Glenohumeral Osteoarthritis | Small molecule | Musculoskeletal |Pacira BioSciences, Inc.|Last Updated: May 29, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedPLACEBO_CONTROLLED
Total Trials1
Total Enrollment150
FDA Designations
No designations recorded
Clinical trial landscape

ZILRETTA · 1 trial · 1 indication

Phase 3 1
NCT06269705ZILRETTA in Subjects With Shoulder OsteoarthritisGlenohumeral Osteoarthritis
ACTIVE NOT_RECRUITING150 Analytics
PHASE3ACTIVE NOT_RECRUITING
ZILRETTA in Subjects With Shoulder Osteoarthritis
Glenohumeral Osteoarthritis
NCT06269705150
Unlock trial analytics
Study Endpoints
Primary Endpoints
Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to placebo
Week 12
Secondary Endpoints
Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 12 for ZILRETTA relative to TCA-IR
Week 12
Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 18 for ZILRETTA relative to TCA-IR
Week 18
Change from Baseline on the Worst Daily Pain (24-hr) mean score (0-10 Numeric Rating Scale (NRS); 0 = no pain, 10 = worst possible pain) at Week 2 for ZILRETTA relative to placebo
Week 2
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ZILRETTAEXPERIMENTAL100 subjects will receive 32 mg ZILRETTA
PlaceboPLACEBO_COMPARATOR50 subjects will receive normal saline placebo
Interventions
NameTypeDescription
ZILRETTADRUGIA injection of 32 mg ZILRETTA
PlaceboOTHERIA injection of placebo (normal saline)
Unlock Study Design Details
Eligibility Criteria
Age Range50 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites32

Inclusion Criteria To be included in the trial, participants must fulfill the following criteria: 1. Written informed consent has been obtained prior to initiating any study-specific procedures. 2. Willingness and ability to comply with the study procedures and visit schedules and ability to follo...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 29, 2026NCT06269705Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMMay 29, 2026NCT06269705Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMMay 29, 2026NCT06269705Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 26, 2026NCT06269705primaryCompletionDate: changed
LOWMay 24, 2026NCT06269705studyFirstPostDate: changed